Discover what the next wave of AI-assisted drug discovery looks like and how it can help biotech - the AI and physics combo.

Ghent is boosting its biopharma hub with cutting-edge infrastructure, world-class research, and a thriving life sciences ...

An end-of-the-year slowdown has not been witnessed by the biopharma industry yet, and certainly not in the biotech deals ...

The companies Cogent Biosciences, Braveheart Bio, and AAVantgarde bagged the biggest biotech funding rounds overall in ...

Igyxos’ IGX12 brings a fresh approach to infertility treatment, aiming to improve outcomes for both men and women.

Delve into Vandria's technology and its Alzheimer's candidate, VNA-318, the first mitophagy-based candidate in Alzheimer's in ...

In one of the standout deals of the year so far, Roche entered into a $5.3 billion collaboration and license agreement with peptide therapeutics company Zealand Pharma to co-develop and ...

The emergence of dual-payload antibody-drug conjugates (ADCs) and peptide-drug conjugates (PDCs) could mark a significant evolution in targeted therapeutics. Unlike traditional single-payload designs, ...

In the life science industry, the rise of more complex biologics like bispecific antibodies, fusion proteins and antibody-drug conjugate (ADC) therapies are placing new demands on development ...

For over a hundred years, psychiatry has existed at the intersection of science and art. Unlike other fields of medicine, which rely on blood tests, cultures, imaging, or tissue samples for diagnosis, ...

Synthetic biology (SynBio) has stopped dividing itself by categories — red, yellow, green, blue, white — medicine, environment, agriculture, water, and industry —and is now united as one movement, ...

Mapping how T-cell leukemia develops, a team of researchers at the Wellcome Sanger Institute, Great Ormond Street Hospital, University College London, and Addenbrooke’s Hospital in the U.K. identified ...